EP3694560A1 - Nanovecteurs et utilisations - Google Patents
Nanovecteurs et utilisationsInfo
- Publication number
- EP3694560A1 EP3694560A1 EP18803733.7A EP18803733A EP3694560A1 EP 3694560 A1 EP3694560 A1 EP 3694560A1 EP 18803733 A EP18803733 A EP 18803733A EP 3694560 A1 EP3694560 A1 EP 3694560A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- nanoparticles
- solution
- nanoparticle
- nanovector
- active substances
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002539 nanocarrier Substances 0.000 title abstract 3
- 239000013543 active substance Substances 0.000 claims abstract description 76
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 43
- 238000011282 treatment Methods 0.000 claims abstract description 36
- 239000002105 nanoparticle Substances 0.000 claims description 209
- 239000000243 solution Substances 0.000 claims description 193
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 110
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 66
- 229910052697 platinum Inorganic materials 0.000 claims description 62
- -1 polysiloxane Polymers 0.000 claims description 50
- 229910052751 metal Inorganic materials 0.000 claims description 47
- 229920001296 polysiloxane Polymers 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 38
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 34
- 229960004679 doxorubicin Drugs 0.000 claims description 31
- 239000002738 chelating agent Substances 0.000 claims description 29
- 230000008685 targeting Effects 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 28
- 239000002184 metal Substances 0.000 claims description 27
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 23
- 239000000126 substance Substances 0.000 claims description 21
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 17
- 230000001093 anti-cancer Effects 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 14
- 238000004375 physisorption Methods 0.000 claims description 14
- 150000001768 cations Chemical class 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 11
- 238000002512 chemotherapy Methods 0.000 claims description 10
- 230000003993 interaction Effects 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 238000001959 radiotherapy Methods 0.000 claims description 9
- 239000003186 pharmaceutical solution Substances 0.000 claims description 8
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 7
- 229910052797 bismuth Inorganic materials 0.000 claims description 7
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 7
- 229910052710 silicon Inorganic materials 0.000 claims description 7
- 230000009471 action Effects 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 5
- 229910018540 Si C Inorganic materials 0.000 claims description 5
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims description 5
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 5
- 238000012544 monitoring process Methods 0.000 claims description 5
- 239000010703 silicon Substances 0.000 claims description 5
- 229910010271 silicon carbide Inorganic materials 0.000 claims description 5
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- 229960000975 daunorubicin Drugs 0.000 claims description 4
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 4
- 229960004768 irinotecan Drugs 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- 230000000637 radiosensitizating effect Effects 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 4
- 229960004528 vincristine Drugs 0.000 claims description 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 4
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 3
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 3
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 3
- FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical compound OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 claims description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 3
- 108010006654 Bleomycin Proteins 0.000 claims description 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 3
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 3
- 108010092160 Dactinomycin Proteins 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 3
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 3
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 3
- 108010069236 Goserelin Proteins 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 3
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 3
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 3
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 3
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims description 3
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims description 3
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 3
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 claims description 3
- 229960000853 abiraterone Drugs 0.000 claims description 3
- 229930183665 actinomycin Natural products 0.000 claims description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 3
- 229960002756 azacitidine Drugs 0.000 claims description 3
- 229960002170 azathioprine Drugs 0.000 claims description 3
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 3
- 229960001561 bleomycin Drugs 0.000 claims description 3
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 3
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 3
- 229960001467 bortezomib Drugs 0.000 claims description 3
- 229960004117 capecitabine Drugs 0.000 claims description 3
- 229960004562 carboplatin Drugs 0.000 claims description 3
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 3
- 229960004630 chlorambucil Drugs 0.000 claims description 3
- 230000000536 complexating effect Effects 0.000 claims description 3
- 229960004397 cyclophosphamide Drugs 0.000 claims description 3
- 229960000684 cytarabine Drugs 0.000 claims description 3
- 229960003668 docetaxel Drugs 0.000 claims description 3
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 claims description 3
- 229950005454 doxifluridine Drugs 0.000 claims description 3
- 229960001904 epirubicin Drugs 0.000 claims description 3
- 229930013356 epothilone Natural products 0.000 claims description 3
- 150000003883 epothilone derivatives Chemical class 0.000 claims description 3
- 229960001433 erlotinib Drugs 0.000 claims description 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 3
- 229960005420 etoposide Drugs 0.000 claims description 3
- 229960005167 everolimus Drugs 0.000 claims description 3
- 229960002949 fluorouracil Drugs 0.000 claims description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 3
- 229960005277 gemcitabine Drugs 0.000 claims description 3
- 229960002913 goserelin Drugs 0.000 claims description 3
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims description 3
- 229960001507 ibrutinib Drugs 0.000 claims description 3
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 3
- 229960002411 imatinib Drugs 0.000 claims description 3
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 3
- 229960004942 lenalidomide Drugs 0.000 claims description 3
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims description 3
- 229960004961 mechlorethamine Drugs 0.000 claims description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 3
- 229960001428 mercaptopurine Drugs 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 3
- 229960001156 mitoxantrone Drugs 0.000 claims description 3
- 229950007221 nedaplatin Drugs 0.000 claims description 3
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims description 3
- 229960001346 nilotinib Drugs 0.000 claims description 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 3
- 229960001756 oxaliplatin Drugs 0.000 claims description 3
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims description 3
- 229960005079 pemetrexed Drugs 0.000 claims description 3
- 229930002330 retinoic acid Natural products 0.000 claims description 3
- 229960003787 sorafenib Drugs 0.000 claims description 3
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 3
- 229960001796 sunitinib Drugs 0.000 claims description 3
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 3
- 229960001278 teniposide Drugs 0.000 claims description 3
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims description 3
- 229960003087 tioguanine Drugs 0.000 claims description 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 3
- 229960000303 topotecan Drugs 0.000 claims description 3
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 claims description 3
- 229960000653 valrubicin Drugs 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 3
- 229960003862 vemurafenib Drugs 0.000 claims description 3
- 229960003048 vinblastine Drugs 0.000 claims description 3
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 3
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims description 3
- 229960004355 vindesine Drugs 0.000 claims description 3
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 claims description 2
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims description 2
- 230000002301 combined effect Effects 0.000 claims description 2
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims description 2
- 190000008236 carboplatin Chemical compound 0.000 claims 2
- 190000005734 nedaplatin Chemical compound 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 47
- 239000012498 ultrapure water Substances 0.000 description 47
- 150000004756 silanes Chemical class 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 26
- QQGYZOYWNCKGEK-UHFFFAOYSA-N 5-[(1,3-dioxo-2-benzofuran-5-yl)oxy]-2-benzofuran-1,3-dione Chemical compound C1=C2C(=O)OC(=O)C2=CC(OC=2C=C3C(=O)OC(C3=CC=2)=O)=C1 QQGYZOYWNCKGEK-UHFFFAOYSA-N 0.000 description 22
- 238000001914 filtration Methods 0.000 description 18
- 238000000862 absorption spectrum Methods 0.000 description 15
- 239000006228 supernatant Substances 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000004090 dissolution Methods 0.000 description 12
- 230000007935 neutral effect Effects 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 11
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 10
- 229910000077 silane Inorganic materials 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 9
- 229910052782 aluminium Inorganic materials 0.000 description 9
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 9
- 239000002872 contrast media Substances 0.000 description 9
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 239000002502 liposome Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 125000000962 organic group Chemical group 0.000 description 7
- 239000008363 phosphate buffer Substances 0.000 description 7
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 239000002534 radiation-sensitizing agent Substances 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000002725 brachytherapy Methods 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 238000002189 fluorescence spectrum Methods 0.000 description 4
- 238000005558 fluorometry Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000005580 one pot reaction Methods 0.000 description 4
- SCPYDCQAZCOKTP-UHFFFAOYSA-N silanol Chemical compound [SiH3]O SCPYDCQAZCOKTP-UHFFFAOYSA-N 0.000 description 4
- 238000002798 spectrophotometry method Methods 0.000 description 4
- LFQCEHFDDXELDD-UHFFFAOYSA-N tetramethyl orthosilicate Chemical compound CO[Si](OC)(OC)OC LFQCEHFDDXELDD-UHFFFAOYSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 206010015866 Extravasation Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 229910052765 Lutetium Inorganic materials 0.000 description 3
- 229910052769 Ytterbium Inorganic materials 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 150000001412 amines Chemical group 0.000 description 3
- 239000013522 chelant Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000036251 extravasation Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- XDLOGHYCUQYEKA-UHFFFAOYSA-N 2-(1,4,7,10-tetrazacyclododec-1-yl)acetic acid Chemical compound OC(=O)CN1CCNCCNCCNCC1 XDLOGHYCUQYEKA-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 229910052691 Erbium Inorganic materials 0.000 description 2
- 229910052693 Europium Inorganic materials 0.000 description 2
- 229910052689 Holmium Inorganic materials 0.000 description 2
- 206010020843 Hyperthermia Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 229910052779 Neodymium Inorganic materials 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 229910052771 Terbium Inorganic materials 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 229940028652 abraxane Drugs 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000009920 chelation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000011258 core-shell material Substances 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002019 doping agent Substances 0.000 description 2
- 229940115080 doxil Drugs 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 230000036031 hyperthermia Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052738 indium Inorganic materials 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 235000013980 iron oxide Nutrition 0.000 description 2
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 2
- 229910052747 lanthanoid Inorganic materials 0.000 description 2
- 150000002602 lanthanoids Chemical class 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 150000004706 metal oxides Chemical group 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229960003330 pentetic acid Drugs 0.000 description 2
- 238000001126 phototherapy Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 229910001848 post-transition metal Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229910052761 rare earth metal Inorganic materials 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 125000005372 silanol group Chemical class 0.000 description 2
- 238000003980 solgel method Methods 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000000015 thermotherapy Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- 229910052726 zirconium Inorganic materials 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NKIJBSVPDYIEAT-UHFFFAOYSA-N 1,4,7,10-tetrazacyclododec-10-ene Chemical compound C1CNCCN=CCNCCN1 NKIJBSVPDYIEAT-UHFFFAOYSA-N 0.000 description 1
- MDAXKAUIABOHTD-UHFFFAOYSA-N 1,4,8,11-tetraazacyclotetradecane Chemical compound C1CNCCNCCCNCCNC1 MDAXKAUIABOHTD-UHFFFAOYSA-N 0.000 description 1
- JFJNVIPVOCESGZ-UHFFFAOYSA-N 2,3-dipyridin-2-ylpyridine Chemical compound N1=CC=CC=C1C1=CC=CN=C1C1=CC=CC=N1 JFJNVIPVOCESGZ-UHFFFAOYSA-N 0.000 description 1
- GXVUZYLYWKWJIM-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanamine Chemical compound NCCOCCN GXVUZYLYWKWJIM-UHFFFAOYSA-N 0.000 description 1
- FDSYTWVNUJTPMA-UHFFFAOYSA-N 2-[3,9-bis(carboxymethyl)-3,6,9,15-tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-6-yl]acetic acid Chemical compound C1N(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC2=CC=CC1=N2 FDSYTWVNUJTPMA-UHFFFAOYSA-N 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101150015280 Cel gene Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229910052692 Dysprosium Inorganic materials 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- QBDWSGKUAMDWMB-UHFFFAOYSA-N acetic acid;n'-(3-trimethoxysilylpropyl)ethane-1,2-diamine Chemical compound CC(O)=O.CO[Si](OC)(OC)CCCNCCN QBDWSGKUAMDWMB-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940060205 adagen Drugs 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- GRHLMSBCOPRFNA-UHFFFAOYSA-M azanide 2-oxidoacetate platinum(4+) Chemical compound N[Pt]1(N)OCC(=O)O1 GRHLMSBCOPRFNA-UHFFFAOYSA-M 0.000 description 1
- 229910001451 bismuth ion Inorganic materials 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229940107841 daunoxome Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052735 hafnium Inorganic materials 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- KLEAIHJJLUAXIQ-JDRGBKBRSA-N irinotecan hydrochloride hydrate Chemical compound O.O.O.Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 KLEAIHJJLUAXIQ-JDRGBKBRSA-N 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- 108700007621 mifamurtide Proteins 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940048191 onivyde Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000002165 photosensitisation Effects 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 229910001404 rare earth metal oxide Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- SARBMGXGWXCXFW-GJHVZSAVSA-M sodium;2-[[(2s)-2-[[(4r)-4-[[(2s)-2-[[(2r)-2-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]propanoyl]amino]ethyl [(2r)-2,3-di(hexadecanoyloxy)propyl] phosphate;hydrate Chemical compound O.[Na+].CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP([O-])(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O SARBMGXGWXCXFW-GJHVZSAVSA-M 0.000 description 1
- INEPLXDYNFVQCD-UHFFFAOYSA-M sodium;3-trihydroxysilylpropanoate Chemical compound [Na+].O[Si](O)(O)CCC([O-])=O INEPLXDYNFVQCD-UHFFFAOYSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000012306 spectroscopic technique Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000006557 surface reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
- A61K49/128—Linear polymers, e.g. dextran, inulin, PEG comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1878—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating
- A61K49/1881—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating wherein the coating consists of chelates, i.e. chelating group complexing a (super)(para)magnetic ion, bound to the surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
Definitions
- the present invention relates to the field of nanovectors for the delivery of active substances in the body, in particular for the treatment of tumors.
- the use of these nanovectors makes it possible to improve the pharmacokinetics of the active substances with a more selective delivery, for example in tumor tissues.
- nanoparticles for biomedical purposes (CA Schultz et al., Nanomedicine, 2013). Of these nanosystems, more than 20% of them are dedicated to cancer treatment through drug delivery.
- nanoparticles for drug delivery has indeed a number of advantages over direct intravenous injection of free chemotherapy: (i) increased solubility of the drug, (ii) improved pharmacokinetics, (iii) half-life in the prolonged blood circulation (45 hours for Doxil® compared with 10 hours for free doxorubicin) (AC Anselmo et al, Journal of Controlled Release, 2015), (iv) minimization of side effects related to delivery to non-target organs (Q. Qu et al., Advanced Drug Delivery Reviews, 2016).
- inorganic nanoparticles have also been developed. With the exception of iron oxides for MRI (Endorem®, GastroMAR TM, Resovist® 7), none had yet reached the market in 2013 (CA Schultz et al, Nanomedicine, 2013) often for reasons of potential toxicity.
- One of the motivations for developing inorganic nanoparticles for biomedical applications is to take advantage of properties that can emerge at the nano scale: magnetic hyperthermia for iron oxides (Nanotherm®) (K. Maier-Hauff et al, Journal of Neurooncology, 2011), optic hyperthermia for gold nanoparticles (AuroShell®) (JM Stern et al, International Journal of Toxicology, 2016) ...
- porous inorganic nanosystems have been developed for drug delivery.
- mesoporous silica nanoparticles which have been proposed for applications in oncology in the early 2000s (Vallet-Regi et al., Chem. good biocompatibility and low cytotoxicity.
- the pores of these nanoparticles can be obtained between 2 and 50 nm for objects having sizes ranging from 10 nm to micron (Y. Yang, Nanomedicine: NBM, 2016) for specific surfaces of between 200 and 1000 m 2 . g "1.
- mesoporous silica nanoparticles having a size less than 50 nm are difficult to synthesize and tend to aggregate (F. Lu et al, Small, 2009).
- the inventors have indeed found that it was possible to use the recent strategies for synthesizing stable nanoparticles of polysiloxane with a hydrodynamic diameter of less than 5 nm (for example F. Lux et al., Angewandte Chemistry International Edition, 2010) for the development of new nanovectors for drug delivery, said nanovectors being loaded by simple physisorption of the active substances on the surface of ultrafine nanoparticles based on polysiloxane.
- the high surface area / volume ratio of these ultrafine nanoparticles makes it possible to obtain a high active surface charge rate for the nanovectors.
- the nanoparticles also have metal chelates on their surface assuring them a multi-modality, especially as a contrast agent or radiosensitizer.
- the present disclosure thus relates to a process for preparing a nanovector for the delivery of active substances in humans or animals, said process comprising mixing two solutions that can be administered in humans or animals:
- a first solution comprising nanoparticles, said nanoparticles being chosen from nanoparticles based on polysiloxane, with an average diameter of less than 10 nm, preferably less than 5 nm, and
- a second solution comprising an active substance or a mixture of active substances chosen from organic molecules, preferably having a molecular mass of between 2 and 40% of the molecular weight of said articulated nanop, preferably between 5 and 25% of the mass; molecular of said nanoparticle under conditions of concentration ratios, pH, and temperature allowing a physisorption interaction of the active substances on the surface of said nanoparticles.
- the term "nanovector” denotes a particulate pharmaceutical system, characterized by: a biocompatible structure (which does not induce toxic reactions),
- Nanoparticles that can be used in the preparation of nanovectors refers to the nanovector with its active substance charge. Nanoparticles that can be used in the preparation of nanovectors
- nanoparticles that can be used in the preparation of nanovectors comprise two essential characteristics: they are based on polysiloxane,
- mean diameter means the harmonic mean of the diameters of the particles.
- size distribution of nanoparticles is for example measured using a commercial particle size analyzer, such as a Malvern Zeta Sizer Nano-S granulometer based on the PCS (Photon Correlation Spectroscopy) which is characterized by a mean hydrodynamic diameter. A method of measuring this parameter is also described in ISO 13321: 1996.
- nanoparticles based on polysiloxane is meant nanoparticles characterized by a silicon mass percentage of at least 8%.
- polysiloxane an inorganic crosslinked polymer consisting of a chain of siloxanes.
- R is an organic molecule bonded to silicon by a covalent bond Si-C n is an integer between 1 and 4.
- polysiloxane especially includes the polymers resulting from condensation by the tetraethylorthosilicate (TEOS) sol gel method and aminopropyltriethoxysilane (APTES).
- TEOS tetraethylorthosilicate
- APTES aminopropyltriethoxysilane
- the nanoparticles that can be used in the preparation of nanovectors are nanoparticles based on polysiloxane and chelates complexed or not with metallic elements. In this preferred mode, they comprise or consist essentially of the following elements:
- chelating agent means an organic group capable of complexing a metal cation.
- the chelating agent is selected from those whose complexation constant log (Kci) is greater than 15, preferentially with respect to the targeted metal cation.
- Kci complexation constant log
- the function of the chelating agent is to complex the possible inorganic elements of the nanovector (metal cations for example) and to reduce their release after the administration of the nanovector in humans or animals.
- the chelating agent can be obtained by grafting (covalent bonding) on the nanoparticle of one of the following products (before grafting on the nanoparticle): polycarboxylic acids polyamines and their derivatives, and more preferably still in the group consisting of DOTA (1,4,7,10-tetraazacyclododecane-N, N ', N ", N" -tetraacetic acid), DTPA (diethylene triamine penta-acetic acid), OD3A-pyridine of formula (I), below:
- EDTA (2,2 ', 2 ", 2"' - (ethane-1,2-diyldinitrilo) tetraacetic acid), EGTA (ethylene glycol-bis (2-aminoethylether) -N, N, N ', N'- tetraacetic), BAPTA (1,2-bis (o-aminophenoxy) ethane-N, N, N ', N'-tetraacetic acid), NOTE (1,4,7-triazacyclononane-1,4,7-triacetic acid) , PCTA (3,6,9,15-tetraazabicyclo [9.3.1 Jpentadeca- 1 (15), 11,13-triene-3,6,9-triacetic acid), DOTAGA (2- (4,7, -tris (carboxymethyl) -1,4,7,10-tetraazacyclododecan (1-yl) pentanedioic), and TMPAC of formula (II) below:
- said above chelating agents are linked directly or indirectly by covalent bonding to the polysiloxane silicias of the nanoparticle.
- "Indirect” binding means the presence of a molecular "linker” or “spacer” between the nanoparticle and the chelating agent, said linker or spacer being covalently bound to one of the constituents of the nanoparticle.
- the chelating agent is obtained by grafting DOTAGA onto the nanoparticle.
- the nanoparticles that can be used for the preparation of the nanovectors do not comprise metallic elements.
- the nanoparticles may comprise metallic elements, in an ionic form, for example a cation, or not.
- the metal cations which may be complexed by chelating agents and, in particular, according to the desired applications, the alkaline-earth metal cations, may preferably be chosen.
- the metal elements are chosen from alkaline earth metal cations and especially magnesium and / or calcium.
- the metallic elements are chosen from metal cations of high atomic number Z.
- high Z element reference will be made to an element (in its ionic or non-ionic form) of atomic number Z at least greater than 40, preferably greater than 50.
- the metallic elements of high atomic number Z are particularly useful for combined uses of nanovectors for delivery of anti-cancer substances and an action as a contrast agent in a scanner or as a radiosensitizer in radiotherapy.
- the metal elements can also be selected from the appropriate isotopes.
- nanovector for delivery of anticancer substances and magnetic resonance imaging, one can also choose metal elements with appropriate magnetic properties.
- the transition metals include Hf, Cu, Pt, Au, Te, Y, Mn, Ru, Fe, Zr, and mixtures thereof.
- Post-transition metals include Bi, Ga, In and mixtures thereof.
- the rare earth metals include lanthanides such as Gd, Dy, Eu, Tb, Nd, Yb, Er, Ho, Lu and mixtures thereof, and preferably Gd.
- Gd, Dy, Mn and Fe are particularly useful for use as a contrast agent in Magnetic Resonance Imaging (MRI).
- Eu, Tb, Nd, Yb and Er are more particularly useful for use as fluorescence imaging agents.
- Lu, Yb, Gd, Bi, Hf, and Ho are particularly useful for use as a radiosensitizer.
- Cu, Ga, Te, Y, In and Zr are particularly useful for use as a scintigraphic probe.
- the high Z element ratio by nanoparticle is between 5 and 100 nanoparticle-raised Z elements, preferably between 5 and 20.
- the nanoparticles comprise: polysiloxanes,
- DOTAGA as a chelating agent covalently bound to polysiloxanes, Gd 3+ cations complexed with chelating agents.
- Nanoparticles based on polysiloxane and metal element chelates are well known to those skilled in the art. Preferred embodiments are described in particular in the following publications: WO2011 / 135101, WO2013 / 153197.
- a more particularly preferred embodiment for the preparation of the nanovectors according to the present disclosure are nanoparticles called "ultrafine” or “without inorganic core", based on polysiloxane and with an average diameter of less than 10 nm, or even less than 5 nm. .
- ultrafine nanoparticles indeed combine the advantages of multi-modality and passive targeting of tumors (without the presence of targeting molecules on their surface), in particular by EPR effect ("Enhanced Permeability and Retention"). They are therefore particularly suitable for the preparation of nanovectors according to the present disclosure, especially in combination with anticancer substances for applications in cancer therapy, and in particular in chemotherapy or combination chemotherapy and at least one other therapy selected from radiotherapy or brachytherapy.
- the ultrafine nanoparticles can be characterized by the following formula (I):
- N is between 20 and 5000, preferably between 20 and 200.
- ⁇ m is greater than n and less than 4 n
- ⁇ o is between 0 and 2 n
- ⁇ Chi, Ch 2 and Ch 3 are potentially chelating organic groups, identical or different, connected to the Si polysiloxanes by a covalent bond Si- C; a, b and c are integers between 0 and n and a + b + c is less than or equal to n, preferably a + b + c is between 5 and 100, for example between 5 and 20,
- Gf are targeting grafts, identical or different from each other, each linked to Si by an Si-C bond and derived from the grafting of a targeting molecule allowing the targeting of nanoparticles to biological tissues of interest, for example to tumor tissue, f is an integer between 0 and n.
- the ultrafine nanoparticle has the following chemical formula (II):
- nanoparticles preferably have a mean diameter of less than 5 nm.
- nanoparticles of formula (I) or (II) are hereinafter referred to as "ultrafine nanoparticles".
- the ultrafine nanoparticles can be obtained by an original "top-down” process whose essential steps are as follows: a, the preparation of an inorganic metal element oxide core (M), M being preferably chosen from the rare earths and the transition elements, possibly doped with a dopant (D), D being a metallic element different from M chosen from among the rare earths, and / or the transition elements. b the synthesis of a polysiloxane shell around the metal oxide core (M), by sol-gel condensation,
- a precursor nanoparticle of the core / shell type is prepared with a metal element core, for example rare earth oxide, by polyol modified with a polysiloxane shell by sol / gel synthesis, this object has for example a size between 5 and 10 nm.
- an inorganic metal oxide core of very small size can be prepared in an alcohol by one of the methods described in the following publications (P. Perriat et al, J. Coll. Int.Sci, 2004, 273, 191, O. Tillement et al, J. Am Chem Soc, 2007, 129, 5076 and P. Perriat et al, J. Phys Chem, 2009, 113, 4038. ).
- these inorganic cores can be coated with a polysiloxane layer by following for example a protocol described in the following publications: C. Louis et al, Chem. Mat., 2005, 17, 1673 and O. Tillement et al., J. Am. Chem. Soc., 2007, 129, 5076.
- the nanoparticles can then be separated from the synthesis residues by a tangential dialysis or filtration method, on a membrane comprising pores of suitable size.
- the inorganic core is destroyed by dissolution after transfer to an aqueous medium (for example by modifying the pH or by providing chelating agents in the solution).
- This destruction of the inorganic core then makes it possible to scatter the polysiloxane layer (according to a mechanism of collapse or slow corrosion), which finally makes it possible to obtain the ultrafine nanoparticle, that is to say a polysiloxane object. of complex morphology whose characteristic dimensions are of the order of magnitude of the thickness of the initial polysiloxane layer.
- the ultrafine nanoparticle has a high content of chelating agent and metal element since these are grafted initially to the surface of the polysiloxane and at these very small sizes, the surface concerns a very high proportion of the material of the particle, the surface-to-volume ratio varies depending on the size in 1 / r (radius). During the collapse mechanism of this structure, other complexes can also settle to saturation on newly formed "fresh" surfaces. Complexing contents are thus much higher than those which would have been obtained by conventional surface functionalization of finer silica particles, subject to the availability of such particles.
- the ratio of chelating agent per nanoparticle may be between 5 and 100 and preferably between 5 and 20.
- Removing the core thus makes it possible to pass from an average particle diameter of about 5 nanometers or more, to sizes less than 5 nm.
- this operation makes it possible to increase the number of metal element M (eg gadolinium) by nm 3 in comparison with a theoretical polysiloxane nanoparticle of the same size but comprising M (eg gadolinium) only at the surface.
- the number of metal element M for a nanoparticle size is evaluable thanks to the atomic ratio M / Si measured by EDX or by elemental analysis. It is generally substantially similar to the number of chelating agent per nanoparticle, and for example between 5 and 100 and preferably between 5 and 20.
- the ultrafine nanoparticles without an inorganic core with a diameter of less than 10 nm and comprising polysiloxanes, and optionally chelates of metal elements can be obtained by the following method:
- the "one pot” synthetic method comprises mixing at least one negatively charged silane at physiological pH with at least one neutral silane at physiological pH, and / or at least one silane positively charged at physiological pH, wherein: the molar ratio A of the number of neutral silanes on the number of negatively charged silanes is between: 0 A A 6 6, preferably 0.5 A A 2 2;
- the molar ratio B of the number of positively charged silanes on the number of negatively charged silanes is between: 0.25 B B 3 3, preferably 0.5 B B 2 2;
- the molar ratio C of the number of positively charged or neutral silanes on the number of negatively charged silanes is between: 0 C C 8 8, preferably 1 C C 4 4;
- the nanoparticles can then incorporate additional molecules such as chelating agents or targeting grafts.
- physiological pH corresponds to a pH of 7.4.
- silane refers to compounds comprising a silicon atom surrounded by 4 substituents.
- the silanes are selected from alkoxysilanes, hydroxysilanes and mixtures thereof.
- the following examples are examples of silanes that can be used in this method of production: tetraethyl orthosilicate (Si (OC 2 H 5 ) 4 , also called TEOS), tetramethyl orthosilicate (Si (OCH 3 ) 4 , also called TMOS) , (3-aminopropyl) triethoxy silane (H 2 N (CH 2 ) 3 -Si (OC 2 H 5 ) 3 , also known as APTES), APTES-DOTAGA, the trisodium salt of triacid acetic acid N- (trimethoxysilylpropyl) ethylenediamine (( CH 3 O) 3 Si- (CH 2 ) 3 N (CH 2 COONa) (CH 2 ) 2 N (CH 2 COONa)
- silane used herein also includes silane compounds comprising a chelated metal cation.
- silane used herein further includes the compounds derived from the covalent grafting of any targeting agent described below to a silane precursor.
- alkoxysilane means compounds of formula (III): Or :
- R is an organic group
- R 1 is an alkyl group comprising 1 to 12 carbons, preferably 1 to 6 carbons.
- n 0, 1, 2 and 3
- n is 0 or 1.
- hydroxysilane means compounds of formula (IV):
- R is an organic group
- n 0, 1, 2 and 3
- n is 0 or 1.
- organic group used herein refers to any organic group regardless of the functional groups involved linked to the silicon atom by an Si-C bond.
- An example of an organic group includes without limitation alkylamines.
- alkyl group used herein refers to linear or crosslinked alkyl groups. Desired alkyl groups include: methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl and t-butyl, pentyl and its isomers (ie n-pentyl and iso-pentyl) as well as hexyl and its isomers (ie n-hexyl and isohexyl).
- the nanoparticles obtained have a mean diameter of between 0.5 and 15 nm and preferably between 0.5 and 10 nm.
- the silanes (selected from alkoxysilanes, hydroxysilanes and mixtures thereof) may be at least 80, 85 or 90% by weight total reagents.
- the reagents being the starting chemical compounds used for the synthesis of nanoparticles.
- the reaction may be carried out in a protic solvent, such as an alcohol or an aqueous solution.
- a protic solvent such as an alcohol or an aqueous solution.
- the only solvent used is water.
- the reaction is carried out in an alcohol or in mixtures of alcohol.
- the alcohols which can be used for this method of production are included in the list: ethanol, n-propanol, iso-propanol, n-butanol, tert-butanol, n-pentanol, ethylene glycol and diethylene glycol.
- the reaction is preferably carried out in colloidal solution, which allows better control of the size of the nanoparticles.
- the reaction is not carried out by a conventional sol gel process to avoid the formation of crosslinked gels.
- the mixing steps comprise at least one positively charged silane, the positively charged silane comprising at least one positively charged amine function.
- the APTES is an example of a silane comprising a positively charged amine function.
- the reaction comprises mixing at least one negatively charged hydroxysilane or alkoxysilane at physiological pH and comprising at least one chelating agent with: at least one neutral hydroxysilane or alkoxysilane at physiological pH, and / or at least one hydroxysilane or alkoxysilane positively charged at physiological pH and comprising an amine function, where: the molar ratio A of the number of neutral silanes on the number of negatively charged silanes is between: 0 A A 6 6, preferably 0.5 A A 2 2;
- the molar ratio B of the number of positively charged silanes on the number of negatively charged silanes is between: 0 B B 5 5, preferably 0.25 B B 4 4;
- the molar ratio C of the number of silanes positively charged or neutral on the number of negatively charged silanes is between: 0 C C 8 8, preferably 1 C C
- the synthesis comprises a mixture of at least one negatively charged alkoxysilane at physiological pH, said alkoxysilane being selected from APTES-DOT AGA, TANED and CEST and their mixtures with: at least one neutral alkoxysilane at physiological pH, said alkoxysilane being chosen from among TMOS, TEOS and their mixtures, and / or
- the APTES which is positively charged at physiological pH where: the molar ratio A of the number of neutral silanes on the number of negatively charged silanes is between: 0 A A 6 6, preferably 0.5 A A 2 2;
- the molar ratio B of the number of positively charged silanes on the number of negatively charged silanes is between: 0 B B 5 5, preferably 0.25 B B 4 4;
- the molar ratio C of the number of silanes positively charged or neutral on the number of negatively charged silanes is between: 0 C C 8 8, preferably 1 C C
- the synthesis comprises the mixture of APTES-DOTAGA which is negatively charged at physiological pH and: at least one neutral alkoxysilane at physiological pH, said alkoxysilane being chosen from among TMOS, TEOS and their mixtures, and or
- the APTES which is positively charged at physiological pH where the molar ratio A of the number of neutral silanes on the number of negatively charged silanes is between: 0 A A 6 6, preferably 0.5 A A 2 2;
- the molar ratio B of the number of positively charged silanes on the number of negatively charged silanes is between: 0 B B 5 5, preferably 0.25 B B 4 4;
- the molar ratio C of the number of positively charged or neutral silanes on the number of negatively charged silanes is between: 0 C C 8 8, preferably 1 C C 4 4;
- the nanoparticles may further comprise targeting agents covalently linked directly or indirectly to the silicas of the nanoparticles. Examples of targeting molecules are described below.
- the targeting agents are grafted onto the surface of the nanoparticles and are present in a proportion of between 1 and 20 targeting agents per nanoparticle, and preferably between 1 and 5 targeting agents.
- a conventional coupling with reactive groups present may be used, possibly preceded by an activation step.
- the coupling reactions are known to those skilled in the art and will be chosen according to the structure of the surface layer of the nanoparticle and the functional groups of the targeting molecule. See, for example, "Bioconjugate Techniques," G. T. Hermanson, Academy Press, 1996, in “Fluorescent and Luminescent Probes for Biological Activity,” Second Edition, W. T. Mason, ed. Academy Press, 1999. Preferred coupling methods are described below.
- these targeting molecules are grafted to the chelating agents of nanoparticles according to the variant of ultrafine nanoparticles "without heart” as described in the preceding paragraph.
- Targeting molecules will be chosen according to the intended application. In a particular embodiment, suitable molecules for active targeting of tumors will be selected. As examples of targeting molecules that can be grafted onto the nanoparticles, mention may be made of molecules containing the RGD tripeptide capable of recognizing the integrin ⁇ 3. Such peptides and their derivatives (especially cyclic pentapeptide) are described in particular in WO2004 / 026894. Targeting molecules suitable for the targeting of tumor tissues have been described for example in the international publication WO01 / 00621 and include, quaternary ammonium derivatives, aptamers, polypeptides, antibodies, etc. Active substances used in the preparation of nanovectors
- active substance means:
- the active substances that can be used in the preparation of nanovectors according to the present disclosure are organic molecules.
- organic molecule is meant in the present disclosure a molecule consisting essentially of the following elements: C, H, O, N, P, S. It may be molecules of biological or synthetic origin.
- organic molecule also encompasses for the purpose of the present invention metal-chelating organic compounds, in particular a metal selected from Pt, Ti, Ru, Au and Rh.
- the active substances that can be used in the preparation of the nanovectors are chosen from organic molecules with a molecular mass of between 2 and 40% of the mass of the nanoparticle and preferably between 5 and 25% of the mass of the nanoparticle.
- the active substances that can be used in the preparation of nanovectors are organic molecules with a molar mass of at most 5000 g / mol and preferably between 100 and 2000 g / mol -1 (hereinafter designated "small molecule").
- nucleic acids and in particular oligonucleotides, ribonucleic acids (RNAs), microRNAs, siRNAs (short interfering RNA), or RNAi (interfering RNA).
- RNAs ribonucleic acids
- microRNAs microRNAs
- siRNAs short interfering RNA
- RNAi interfering RNA
- it is peptides of not more than 50 amino acids, for example between 5 and 30 amino acids.
- the active substance is chosen from anti-cancer substances.
- anti-cancer substances mention may be made of the following molecules: actinomycin, all-trans retinoic acid, azacitidine, azathioprine, bleomycin, bortezomib, carboplatin, capecitabine, cisplatin, chlorambucil, cyclophosphamide, cytarabine, daunorubicin, docetaxel, doxifluridine, doxorubicin, epirubicin, epothilone, etoposide, fluorouracil, gemcitabine, hydroxyureal, darubicin, imatinib, irinotecan, mechlorethamine, mercaptopurine, methotrexate, mitoxantrone, oxaliplatin, paclitaxel, pemetrexed, teniposide, tioguanine, to
- the active substance is chosen from doxorubicin, TATE peptide and cis platinum or their mixtures.
- the process for preparing nanovectors according to the present disclosure consists in mixing two solutions that can be administered in humans or animals: a first solution comprising a nanoparticle based on polysiloxane with a mean diameter of less than 10 nm, preferably less than 5 nm, and
- a second solution comprising an active substance or a mixture of active substances under conditions of ratios of concentrations, pH, and temperature allowing interaction by physisorption of the active substances on the surface of said nanoparticles.
- the term "physisorption interaction” means Van der Waals interactions, in particular excluding protein / protein specific ligand / receptor, antigen / antibody or other specific molecule-molecule interactions.
- nanoparticles and active substances used for the preparation of nanovectors and in particular certain preferred modes have been described in the preceding paragraphs.
- the level of charge corresponds to the quantity of active substances associated with the nanovector expressed in mg per gram of nanoparticles.
- the mass concentration ratio [active substances in the second solution]: [nanoparticles in the first solution] is determined to allow a loading rate of active substance greater than 0.5 mg / g, preferably 1 mg / g nanoparticles, for example between 1 mg / g and 100 mg / g.
- a loading rate of active substance greater than 0.5 mg / g, preferably 1 mg / g nanoparticles, for example between 1 mg / g and 100 mg / g.
- the first solution is an aqueous colloidal suspension of nanoparticles (for example ultrafine nanoparticles) at a concentration of between 5 and 500 ⁇ L -1 at a pH of between 6 and 8.
- nanoparticles for example ultrafine nanoparticles
- the second solution is an aqueous solution of active substances at a concentration of between 1 mg.L -1 and 10 gL -1 at a pH of between 6 and 8. .
- the inventors have demonstrated that the active substances can be associated by physisorption on the surface of nanoparticles based on polysiloxane, by simple mixing of the two solutions.
- the present disclosure thus relates to a nanovector for the delivery of active substances in humans, comprising a nanoparticle on the surface of which physisorption-related active substances are bound, characterized in that said nanoparticle is chosen from nanoparticles based on polysiloxane , with an average diameter of less than 10 nm, preferably less than 5 nm, and the active substances are chosen from the molecules organic compounds with a molar mass of between 2 and 40% of the mass of said nanoparticle, preferably between 5 and 25% of the molecular weight of said nanoparticle.
- Such nanovectors can be obtained directly or indirectly by the simple process of mixing the 2 solutions described above.
- the nanovector comprises
- nanoparticles consisting essentially of the following: a. polysiloxanes, characterized by a silicon mass percentage of between 8 and 50%>
- chelating agents preferably in a proportion of between 5 and 100 per nanoparticle, and more preferably between 5 and 20, c. where appropriate, metal elements, for example Gd or Bi, preferably in a proportion of between 5 and 100, and more preferably between 5 and 20, said metal elements being complexed with chelating agents; and
- the nanoparticles are ultrafine nanoparticles as described above.
- ultrafine nanoparticles include DOTAGA grafted on the surface of ultrafine nanoparticles, as a chelating agent and Gd or Bi as a metal element complexed with DOTAGA.
- composition comprising nanovectors
- nanovectors as described above are advantageously formulated for administration to humans with at least one pharmaceutically acceptable excipient.
- the invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising nanovectors according to the present disclosure and at least one pharmaceutically acceptable excipient.
- the pharmaceutical composition is an injectable pharmaceutical solution comprising a nanovector as described above, and at least one pharmaceutically acceptable excipient with an effective dose of active substances.
- the pharmaceutically acceptable excipients may include any amenable component in humans or animals that do not substantially modify the biological activity of the active substances in the body. They are described in particular in the reference book Remington's Pharmaceutical Sciences, Mack Publishing Company.
- said injectable pharmaceutical solution is characterized in that the nanovector comprises a metal element, preferably bismuth or gadolinium, and in that said metallic element is at a concentration of between 5 and 200 mM.
- the injectable pharmaceutical solution is characterized in that the nanovector comprises an anti-cancer active substance.
- the nanovector active substance is selected from doxorubicin, cis-platinum and TATE peptide.
- the injectable pharmaceutical solutions are directly obtained by the step of mixing the two solutions for the preparation of the nanovectors as described above, without a subsequent purification step. It can be prepared in advance, then stored before administration to the patient, or prepared just before administration to the mixture (eg less than 4 hours, less than 3 hours, less than 1 hour, or less than 30 minutes, or less 15 minutes before administration to the patient), by mixing the two solutions.
- the invention relates to a kit for the preparation of injectable nanovectors or solution as described above, the kit comprising at least two separate containers, one comprising the first solution with the nanoparticles, in a form ready for mixing, or concentrated, and the other containing a second solution containing the active substance (s). If necessary, one or both solutions can be replaced by lyophilizates, ready to be diluted in a dilution solution to obtain the aqueous solutions suitable for mixing.
- the said dilution solution (s) optionally included in the kit may further comprise buffers or other pharmaceutically acceptable excipients for administration to humans.
- the nanovectors and injectable solutions described above are particularly useful for the treatment of cancer in humans or animals, said active substance being chosen from the substances anti -cancerous, and in particular cytotoxic substances.
- the present disclosure also relates to a method of treating cancer in a patient, comprising administering to said patient said nanovectors comprising an effective dose of anti-cancer substance as an active substance for the treatment of said cancer.
- the nanovectors according to the present disclosure are particularly useful in the chemotherapy treatment of solid tumors, and in particular: tumors of the central nervous system, of the lung, of the prostate, of the uterus, of the colon, of the pancreas, of the liver, of the kidney, breast, head and neck, or colon.
- tumors of the central nervous system, of the lung, of the prostate, of the uterus, of the colon, of the pancreas, of the liver, of the kidney, breast, head and neck, or colon This list is of course not limiting.
- the nanovectors in addition to their high level of charge in active substances, may also include a high level of charge in radiosensitizing agent, in the form of metal cation chelate.
- the nanovector for its use in the treatment of cancer is characterized in that it comprises nanoparticles comprising element chelates of atomic number greater than 40, with radiosensitizing effect, preferably nanoparticles. ultrafine as described above, and in that the administration of an effective dose of said nanovector in the subject to be treated allows cancer treatment by combined effect of chemotherapy and radiotherapy.
- the active substances should have improved pharmacokinetics and in particular a better targeting of the tumor by EPR effect as found for ultrafine polysiloxane nanoparticles on many preclinical models and described in Detappe et al., Nano Letters 2017; C. Verry et al, Nanomedicine, 2016; Dufort et al, Small 2015; Bianchi et al, PNAS, 2014.
- the nanovector (or solution for injection) according to the present disclosure can be administered preferably intravenously, intratumorally, intraperitoneally, intraarterially or by the airways (for example intranasal or intratracheal), in particular as described in publication WO2013153197.
- the nanovector can also allow a radiotherapy treatment by choosing nanoparticles comprising metal element chelates, for use as a contrast agent, especially in MRI, scanner or scintigraphy.
- the nanovector comprises nanoparticles comprising contrast agents for magnetic resonance imaging, scanning, or scintigraphy, and the administration of an effective dose of said nanovector in the subject to be treated. allows the monitoring of the curative action of the treatment.
- the present disclosure also relates to a method for monitoring the therapeutic efficacy of a therapeutic treatment in humans or animals, said method comprising the following steps:
- the patient is administered nanovectors as defined above, and comprising an effective dose of contrast agent and an effective dose of active substances,
- the images are captured by an appropriate imaging technique to visualize the lesions using the contrast agent
- steps (i) and (ii) are repeated during treatment of the subject, as necessary,
- a particular application of this method relates to monitoring the therapeutic efficacy of a treatment in humans or animals, for example an anti-tumor treatment, for example by chemotherapy, radiotherapy, brachytherapy, phototherapy or thermotherapy. , against solid tumors.
- the invention relates to a method for monitoring the therapeutic efficacy of an anti-tumor treatment in humans or animals, in particular a chemotherapy treatment, and if necessary combined with a treatment. by radiotherapy, brachytherapy, phototherapy or thermotherapy, directed against solid tumors, said method comprising the following steps:
- the cancer patient with solid tumors is administered, at the initiation of the treatment, nanovectors, as defined in the preceding paragraphs, preferably based on ultrafine nanoparticles, comprising an effective dose of anti-cancer agent; contrast and anti-cancer substances,
- the images are captured by an appropriate imaging technique to detect tumors
- steps (i) and (ii) are repeated during the treatment of the patient.
- the therapeutic efficacy of the anti-cancer substances is compared by comparing the images of the tumors obtained during the treatment.
- the evolution of tumors including the size of tumors over time, their number and their distribution, before, during, and after the treatment of the patient.
- the nanovectors may comprise both an effective dose of active substances to the tumors, and, if appropriate, an effective dose of radio-sensitizing, photosensitizing or radioactive agent for the treatment of tumors and / or or an effective dose of contrast agent.
- the nanoparticles used as a contrast agent are the same as those used as radiosensitizing agents.
- Figure 1 General principle of physisorption on nanovectors.
- the active substance is added to the nanoparticles.
- Step 1 the active substance interacts by physisorption on the surface of the nanoparticles.
- Step 2 The active substance saturates the sphere of interaction of nanoparticles.
- Step 3 the active substance can no longer interact with the surface of the nanoparticles and remains free in solution.
- Figure 2 Curve representing the evolution of the concentration of active species of sub-swimming according to the drug concentration in the presence of polysiloxane-based nanoparticles.
- Figure 3 Absorption spectra of subnagants of Examples 1 and 2.
- Figure 5 Absorbance values at 497 nm of the subnants of doxorubicin solutions in the presence of 100 mM AGuIX as a function of the amount of doxorubicin introduced.
- Figure 6 Absorption spectra of subnapents of Examples 6 and 7 diluted 20 times.
- Figure 7 Absorption spectra of subnapents of Examples 9 and 10 diluted 20 times.
- Figure 9 Fluorescence spectrum of the sub-transient of Examples 6 and 7 diluted 20 times.
- FIG. 10 Fluorescence spectrum of the subnapents of Examples 9 and 10 diluted 20 times.
- Figure 11 Fluorescence spectrum of the subagent of Example 8 diluted 20 times.
- Figure 12 Absorbance values at 280 nm of the subnapents of the TATE peptide solutions (diluted 20-fold) in the presence of 100 mM AGuIX as a function of the amount of TATE peptide introduced.
- Figure 13 Absorbance Spectrum of the subnapents of Examples 12, 13 and 14 after treatment as described in the examples.
- Figure 14 Absorbance Spectrum of Subhumans of Examples 15 and 16 after treatment as described in the examples.
- Figure 15 Absorbance Spectrum of Subhumans of Examples 17 and 18 after treatment as described in the examples.
- Figure 16 Absorption values at 706 nm of sub-swim-Cis-platinum solutions in the presence of AGuIX ® 100 mM depending on the amount of introduced Cis-platinum. The subnants were previously treated as described in the examples to allow the detection of cis-platinum absorption.
- Figure 17 Absorbance spectra of the subhumans of Examples 18 and 19 after treatment as described in the previous examples.
- Figure 18 Absorbance Spectrum of Subhumans of Examples 18 and 20 After Treatment as Described in Examples.
- nanoparticles of polysiloxane to act as a transporter of molecules used in chemotherapy.
- the targeted molecules adsorb to the surface of the nanoparticles according to the mechanism proposed in FIG. 1.
- the examples below also make it possible to determine the limit in drug concentration beyond which the drugs are no longer retained on the surface of the nanoparticles. the nanoparticle.
- the maximum loading rate of drugs on nanoparticles of polysiloxane when they are present at a concentration corresponding to a concentration used in clinical trials for the nanoparticle in question, was determined.
- Increasing concentrations of active substances have been brought into contact with the nanoparticles.
- the solutions are purified by tangential filtration. Molecules that could not adsorb to the surface of the nanoparticles pass through the membrane and are found in the sub-swimming where they can be detected by spectroscopic techniques such as UV / Visible absorption or fluorescence spectroscopy ( Figure 2).
- a solution of AGuIX ® at a concentration of 10 mM gadolinium is analyzed by DLS with a laser at 633 nm. A hydrodynamic diameter in number of 3.2 nm is obtained.
- Example 1 50 ⁇ (Gd 3+ ) of AGuIX ® nanoparticles were redispersed in 125 ⁇ l of ultrapure water to obtain a 400 mM solution ([Gd 3+ ]). 2.85 mg of doxorubicin are placed in a 2.5 mL vial. 1.1 ml of ultra-pure water is added to the vial, which is stirred until the doxorubicin is completely dissolved. A solution of 2.6 g / L of doxorubicin is then obtained, and is protected from light by aluminum. 215 of this solution are then added to the AGuIX ® solution as well as 160 ⁇ L of ultrapure water. The flask is stirred for 30 minutes in the dark.
- a solution of 100 mM gadolinium, and 112 mg / L doxorubicin is obtained. This solution is placed in a Vivaspin® 3 kDa, and a tangential filtration cycle is performed to obtain a 200 ⁇ supernatant. The sub-swimming is analyzed by UV-visible. The supernatant is diluted by 50 and is analyzed by UV-visible.
- Example 2 (Comparative): A solution of doxorubicin at 112 mg / L is prepared according to the procedure described in Example 1, replacing the AGuIX® solution with ultrapure water.
- Example 3 50 ⁇ (Gd 3+) of AGuIX ® nanoparticles were redispersed in 125 ⁇ xL of ultrapure water to make a 400 mM solution [Gd 3+]. 2.85 mg of doxorubicin are placed in a 2.5 mL vial. 1.1 mL of ultra-pure water is added to the vial, which is stirred until the doxorubicin is completely dissolved. A solution of 2.6 g / L of doxorubicin is then obtained, and is protected from light by aluminum. 327 ⁇ of this solution are then added to the AGuIX ® solution as well as 48 ⁇ of ultrapure water. The flask is stirred for 30 minutes in the dark.
- a solution of 100 mM gadolinium, and 170 mg / L doxorubicin is obtained. This solution is placed in a Vivaspin® 3 kDa, and a tangential filtration cycle is performed to obtain a 200 ⁇ supernatant. The sub-swimming is analyzed by UV-visible. The supernatant is diluted by 50 and is analyzed by UV-visible.
- Example 4 (Comparative) A solution of doxorubicin and 170 mg / L was prepared according to the procedure described in Example 3 by replacing the AGuIX ® solution with ultra-pure water.
- Figures 3 and 4 respectively represent the absorption spectra of the sub-swim-solutions of Examples 1 and 2, and solutions of Examples 3 and 4. These data show that doxorubicin interacts with AGuIX ®. Indeed, for the 100 mM solution ([Gd 3]) of AGuIX ® and 112 mg / L, doxorubicin is adsorbed to the surface of the nanoparticle and is not detected in the sub-swimming after tangential filtration unlike to a solution of doxorubicin alone.
- a solution obtained by the procedure of Example 3 (doxorubicin to 170mg / L and AGuIX ® 100 mM [Gd 3+]) is diluted by 50 and analyzed by DLS with a laser at 633 nm. A hydrodynamic diameter in number of 3.7 nm is obtained greater than the diameter of 3.2 nm obtained for AGuIX ® nanoparticles indicating a surface interaction of nanoparticles with doxorubicin.
- Example 6 50 ⁇ (Gd 3+) of AGuIX ® were redispersed in 125 ultrapure water to make a 400 mM solution ([Gd 3+]). 14.94 mg tyr3-octreotate peptide (TATE) are placed in a 2.5 mL vial. 498 ⁇ of ultra-pure water is added to the bottle which is agitated until complete dissolution of the peptide. A 30 g / l solution of peptide is then obtained. 48 ⁇ of this solution are then added to the AGuIX ® solution and 328 ⁇ of ultrapure water. The flask is stirred for 30 minutes. A solution of 100 mM gadolinium, and 2.90 g / L peptide is obtained.
- TATE tyr3-octreotate peptide
- Example 7 (Comparative) A TATE peptide solution at 2.90 g / L was prepared according to the procedure described in Example 6 by replacing the AGuIX ® solution with ultra pure water.
- Example 8 50 ⁇ (Gd 3+ ) of AGuIX® nanoparticles were redispersed in 125 ⁇ of ultrapure water in order to obtain a 400 mM solution ([Gd 3+ ]).
- 6.1 mg peptide tyr3-octreotate (TATE) are placed in a 2.5 mL vial.
- 203.3 ⁇ of ultra-pure water are added to the flask, which is stirred until the peptide is completely dissolved.
- a 30 g / l solution of peptide is then obtained.
- 97 ⁇ of this solution are then added to the AGuIX ® solution and 279 ⁇ of ultrapure water.
- the flask is stirred for 30 minutes.
- a solution of 100 mM gadolinium, and 5.80 g / L peptide is obtained.
- Example 9 50 ⁇ (Gd 3+) of AGuIX ® nanoparticles were redispersed in 125 ⁇ , ultra-pure water to obtain a 400 mM solution ([Gd 3+]). 14.94 mg peptide tyr3-octreotate (TATE) are placed in a 2.5 mL vial. 498 ⁇ of ultra-pure water are added to the bottle which is stirred until complete dissolution of the peptide. A 30 g / l solution of peptide is then obtained. 193 ⁇ of this solution are then added to the AGuIX ® solution and 182 ⁇ of ultrapure water. The flask is stirred for 30 minutes.
- TATE peptide tyr3-octreotate
- Example 10 (Comparative) A TATE peptide solution to 11.60 g / L was prepared according to the procedure described in Example 5 by replacing the AGuIX ® solution with ultra-pure water.
- Example 11 50 ⁇ (Gd 3+) of AGuIX ® nanoparticles were redispersed in 250 ultra-pure water to obtain a solution containing 200 mM ([Gd 3+]). 0.6 mg of tyr3-octreotate peptide (TATE) are placed in a 2.5 mL vial. Ultra-pure water is added to the flask, which is stirred until the peptide is completely dissolved. A 30 g / l solution of peptide is then obtained. 20 ⁇ l of this solution are then added to the AGuIX ® solution and 230 ⁇ l of ultrapure water. The flask is stirred for 30 minutes. A solution of 100 mM gadolinium, and 1.20 g / L peptide is obtained.
- TATE tyr3-octreotate peptide
- FIGS. 6, 7 and 8 respectively show the absorption spectra of the 20-fold subeducts of the solutions of Examples 6 and 7, the solutions of Examples 9 and 10 and the solution of the Example 8. These data show that the peptide TATE adsorbs on the surface of the nanoparticles up to a concentration of approximately 2 gL -1 (FIG. 12), since before this limiting concentration, the TATE peptide is not detected. by UV / VIS spectrophotometry in the subnants of the purified solutions by tangential filtration.
- FIGS. 9, 10 and 11 respectively represent the fluorescence spectra of the 20-fold diluted sub-samples of Examples 6 and 7, Examples 9 and 10 and of Example 8.
- TATE peptide interacts with AGuIX ® .
- a solution obtained by the procedure of Example 8 (TATE at 2.90 g / L) is diluted by 10 and analyzed by DLS with a 633 nm laser.
- a hydrodynamic diameter in number of 3.4 nm is obtained greater than the diameter of 3.2 nm obtained for the AGuIX ® nanoparticles indicating a surface interaction of the nanoparticles with the TATE peptide.
- AGuIX ® nanoparticle solution 100 mM ([Gd 3+]) corresponding to 100 g / L of nanoparticles, a retention TATE peptide is observed up to a concentration of 2 g / L which corresponds to a rate mass load greater than 20 mg / g of nanoparticles ( Figure 12).
- Example 12 50 ⁇ (Gd 3+) of AGuIX ® were redispersed in 125 ultra-pure water to obtain a 400mM solution [Gd 3+].
- 3.1 mg cis platinum are placed in a 2.5 mL vial. 1, 2 mL of ultrapure water is added to the flask which is shaken. Platinum cis is not very soluble at room temperature, it is necessary to heat to 40 ° C until complete dissolution. A 2.5 g / L solution of platinum cis is then obtained, and is protected from light by aluminum. 24 of this solution are then added to the AGuIX ® solution as well as 351 ⁇ of ultrapure water. The flask is stirred for 30 minutes in the dark.
- a solution of 100 mM gadolinium, and 120 mg / L cis platinum is obtained. This solution is placed in a Vivaspin® 3 kDa, and a tangential filtration cycle is performed to obtain a supernatant of 160 ⁇ .
- the sub-swimming is analyzed by UV-visible. Platinum cis is detectable by UV7VIS absorption at a wavelength of 706 nm after reaction with ODPA.
- a solution of ODPA at 1.4 mg / mL and a phosphate buffer (pH 6.8) are prepared. The sub-swimming is diluted by 5. 140 ⁇ , of this solution is added to 200 ⁇ , buffer and 100 ⁇ , ODPA. The resulting solution is heated at 100 ° C for 15 minutes. Once the finished reaction and returning to room temperature, 560 ⁇ ⁇ of DMF are added. The final solution is filtered and analyzed by UV-visible.
- Example 13 50 ⁇ (Gd 3+) of AGuIX ® were redispersed in 125 ⁇ , ultra-pure water to obtain a 400 mM solution ([Gd 3+]).
- 3.1 mg cis platinum are placed in a 2.5 mL vial. 1, 2 mL of ultrapure water is added to the flask which is shaken. Platinum cis is not very soluble at room temperature, it is necessary to heat to 40 ° C until complete dissolution. A 2.5 g / L solution of platinum cis is then obtained, and is protected from light by aluminum. 36 ⁇ ⁇ of this solution are then added to the solution and AGuIX ® 339 ⁇ , ultra-pure water. The bottle is placed under agitation for 30 minutes in the shelter of the light. A solution of 100 mM gadolinium and 180 mg / L cis platinum is obtained.
- This solution is placed in a Vivaspin ® 3 kDa, and a tangential filtration cycle is performed to obtain a supernatant of 160 ⁇ .
- the sub-swimming is analyzed by UV-visible. Platinum cis is detectable by UV / VIS absorption at a wavelength of 706 nm after reaction with ODPA.
- a solution of ODPA at 1.4 mg / mL and a phosphate buffer (pH 6.8) are prepared.
- Submarine is diluted by 5. 140 of this solution are added to 200 of buffer and 100 ⁇ l of ODPA.
- the resulting solution is heated at 100 ° C for 15 minutes. Once the finished reaction and returning to room temperature, 560 ⁇ ⁇ of DMF are added.
- the final solution is filtered and analyzed by UV7VIS spectrophotometry.
- Example 14 50 ⁇ (Gd 3+) of AGuIX ® were redispersed in 125 ⁇ , ultra-pure water to obtain a 400 mM solution ([Gd 3+]). 3.1 mg cis platinum are placed in a 2.5 mL vial. 1.2 mL of ultra-pure water is added to the shake flask. Platinum cis is not very soluble at room temperature, it is necessary to heat to 40 ° C until complete dissolution. A 2.5 g / L solution of platinum cis is then obtained, and is protected from light by aluminum. 72 ⁇ ⁇ of this solution are then added to the solution and AGuIX® 303 ⁇ , ultra-pure water. The flask is stirred for 30 minutes in the dark. A solution of 100 mM gadolinium, and 360 mg / L cis platinum is obtained.
- This solution is placed in a Vivaspin® 3 kDa, and a tangential filtration cycle is performed to obtain a supernatant of 160 ⁇ .
- the sub-swimming is analyzed by UV-visible. Platinum cis is detectable by UV7VIS absorption at a wavelength of 706 nm after reaction with ODPA.
- a solution of ODPA at 1.4 mg / ml and a phosphate buffer (pH 6.8) are prepared.
- the resulting solution is heated at 100 ° C for 15 minutes.
- Example 15 50 ⁇ (Gd 3+) of AGuIX ® were redispersed in 125 ⁇ , ultra-pure water to obtain a 400 mM solution ([Gd 3+]). 2.8 mg of platinum cis are placed in a vial of 2.5 mL. 1.1 mL of ultra-pure water is added to the shake flask. Platinum cis is not very soluble at room temperature, it is necessary to heat to 40 ° C until complete dissolution. A 2.5 g / L solution of platinum cis is then obtained, and is protected from light by aluminum.
- This solution is placed in a Vivaspin ® 3 kDa, and a tangential filtration cycle is performed to obtain a supernatant of 140 ⁇ .
- the sub-swimming is analyzed by UV-visible. Platinum cis is detectable by UV / VIS absorption at a wavelength of 706 nm after reaction with ODPA.
- a solution of ODPA at 1.4 mg / mL and a phosphate buffer (pH 6.8) are prepared.
- the sub-swimming is diluted with 5. 140 of this solution are added to 200 ⁇ ⁇ buffer and 100 ⁇ ⁇ of ODPA.
- the resulting solution is heated at 100 ° C for 15 minutes. Once the finished reaction and returning to room temperature, 560 ⁇ ⁇ of DMF are added.
- the final solution is filtered and then analyzed by UV-visible.
- Example 16 (Comparative): A solution of cis-platinum and 720 mg / L was prepared according to the procedure described in Example 15 by replacing the AGuIX ® solution with ultrapure water.
- Example 17 50 ⁇ (Gd 3+) of AGuIX ® were redispersed in 125 ⁇ , ultra-pure water to obtain a 400 mM solution ([Gd 3+]). 2.8 mg cis platinum are placed in a 2.5 mL vial. 1.1 mL of ultra-pure water is added to the shake flask. Platinum cis is not very soluble at room temperature, it is necessary to heat to 40 ° C until complete dissolution. A 2.5 g / L solution of platinum cis is then obtained, and is protected from light by aluminum. 229 ⁇ of this solution are then added to the AGuIX ® solution and 146 ⁇ of ultrapure water. The flask is stirred for 30 minutes in the dark. A solution of 100 mM gadolinium, and 1160 mg / L cis platinum is obtained.
- This solution is placed in a Vivaspin ® 3 kDa, and a tangential filtration cycle is performed to obtain a supernatant of 160 ⁇ .
- the sub-swimming is analyzed by UV-visible.
- Platinum cis is detectable by UV7VIS absorption at a wavelength of 706 nm after reaction with ODPA.
- a solution of ODPA at 1.4 mg / mL and a phosphate buffer (pH 6.8) are prepared.
- Submarine is diluted by 5. 140 of this solution are added to 200 of buffer and 100 ⁇ l of ODPA.
- the resulting solution is heated at 100 ° C for 15 minutes. Once the finished reaction and returning to room temperature, 560 ⁇ ⁇ of DMF are added.
- the final solution is filtered and analyzed by UV-visible.
- Examples 12, 13, 14, 15 and 17 are analyzed by DLS (10-fold diluted samples) with a 633 nm laser.
- the respective hydrodynamic diameters in number are: 3.8; 3.7; 3.8; 3,4; 3.7 nm. They are greater than the 3.2 nm diameter obtained for AGuIX ® nanoparticles indicating a surface interaction of nanoparticles with platinum cis.
- Example 18 (Comparative): A solution of cisplatin to 1160 mg / L was prepared according to the procedure described in Example 15 by replacing the AGuIX ® solution with ultra pure water.
- FIG. 13 represents the absorbance of the subnapents of Examples 12, 13 and 14 after treatments as described in the examples.
- FIGS. 14 and 15 respectively show the absorption spectra of the subnapents of the solutions of Examples 15 and 16, and the solutions of Examples 17 and 18. These data show that the platinum cis adsorbs on the surface of the nanoparticles up to at a concentration of approximately 240 mg.L- 1 (FIG.
- the solution is purified by a factor of 50 by Vivafiow before being neutralized to pH 7.4 by controlled addition of 1M sodium hydroxide solution is filtered and lyophilized. After re-dispersion in water, the nanoparticles have a hydrodynamic diameter of 5.2 nm.
- This solution is placed in a Vivaspin ® 3 kDa, and a tangential filtration cycle is performed to obtain a supernatant of 200 ⁇ .
- the sub-swimming is analyzed by UV-visible. Platinum cis is detectable by UV / VIS absorption at a wavelength of 706 nm after reaction with ODPA.
- a solution of ODPA at 1.4 mg / mL and a phosphate buffer (pH 6.8) are prepared for the reaction with cis-platinum.
- the sub-swimming is diluted by 5. 140 of this solution are added to 200 ⁇ l of buffer and 100 ⁇ l of ODPA. This new solution is heated to 100 ° C for 15 min.
- FIG. 17 represents the absorption spectra of the subnapents of the solutions of Examples 18 and 19. In the subnagnants a lower signal can be observed for the cis platinum added to the silica nanoparticle solution.
- the 706 nm signal of the two UV spectra makes it possible to estimate a retention of a cis platinum concentration of 260 mg / L for a nanoparticle solution at 125 g / L corresponding to a mass loading rate of 2.1 mg / g of nanoparticles.
- Example 20 Possibility of varying the charge rate by modifying the surface of the nanoparticles by chelation of bismuth ions.
- the nanoparticles described in Example 19 are dispersed in water (283 mg, 227 ⁇ in DOTAGA) in order to have a DOTAGA concentration of approximately 200 mM.
- the pH of the solution is adjusted to 5.5 by adding NaOH. 817 of a solution of B1CI 3 250 mM in 6M HCl are slowly added in 3 times with stirring at a temperature of 70 ° C to accelerate the complexation. Between each addition, the pH is adjusted to 5.5 by slow addition of a 10M sodium hydroxide solution. The solution is then heated at 80 ° C for 1 hour after the last addition. Following this, ultrapure water is added until a chelate concentration of 100 mM is reached at a pH of 5.5.
- the solution is then heated at 80 ° C for 18 h.
- the excess of Bi 3+ is removed by tangential filtration, then the solution is neutralized to reach a pH of 7 by adding sodium hydroxide before membrane filtration 0.2 ⁇ and lyophilization.
- the nanoparticles After re-dispersion in water, the nanoparticles have a hydrodynamic diameter of 6.0 nm.
- Figure 18 shows the absorption spectra of the subnagants of the solutions of Examples 18 and 20.
- the chelation of the bismuth at the surface of the nanoparticles causes non-retention of platinum cis on the surface of the nanoparticles, proving that changes in the number of metal elements chelated on the surface of the nanoparticles make it possible to vary the charge rate of nanoparticles.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Radiology & Medical Imaging (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1759607A FR3072281B1 (fr) | 2017-10-13 | 2017-10-13 | Nanovecteurs et utilisations, en particulier pour le traitement de tumeurs |
PCT/FR2018/052538 WO2019073182A1 (fr) | 2017-10-13 | 2018-10-12 | Nanovecteurs et utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3694560A1 true EP3694560A1 (fr) | 2020-08-19 |
Family
ID=61873369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18803733.7A Pending EP3694560A1 (fr) | 2017-10-13 | 2018-10-12 | Nanovecteurs et utilisations |
Country Status (10)
Country | Link |
---|---|
US (1) | US11857604B2 (fr) |
EP (1) | EP3694560A1 (fr) |
JP (1) | JP7321151B2 (fr) |
KR (1) | KR20200071754A (fr) |
CN (1) | CN111565759B (fr) |
AU (1) | AU2018347740B2 (fr) |
CA (1) | CA3078763A1 (fr) |
FR (1) | FR3072281B1 (fr) |
TW (1) | TWI791640B (fr) |
WO (1) | WO2019073182A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3116197A1 (fr) * | 2020-11-19 | 2022-05-20 | Nh Theraguix | Procédé de traitement de tumeurs par captation du cuivre et/ou du fer |
CN113941005A (zh) * | 2021-10-29 | 2022-01-18 | 上海唯可生物科技有限公司 | 二硫键功能化的二氧化硅纳米粒子、制备、复合物、用途 |
CN117088825A (zh) * | 2023-10-12 | 2023-11-21 | 成都威斯津生物医药科技有限公司 | 一种可离子化脂质、含该可离子化脂质的药物组合物及其用途 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2795412B1 (fr) | 1999-06-23 | 2001-07-13 | Adir | Nouveaux derives d'ammonium quaternaire, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US7531622B2 (en) | 2002-09-19 | 2009-05-12 | Centre National De La Recherche Scientifique- Cnrs | Synthesis and characterization of novel systems for guidance and vectorization of molecules of therapeutic interest towards target cells |
FR2922106B1 (fr) * | 2007-10-16 | 2011-07-01 | Univ Claude Bernard Lyon | Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants. |
US20090208421A1 (en) * | 2008-02-19 | 2009-08-20 | Dominique Meyer | Process for preparing a pharmaceutical formulation of contrast agents |
FR2959502B1 (fr) | 2010-04-30 | 2012-09-07 | Nanoh | Nanoparticules ultrafines a matrice polyorganosiloxane fonctionnalisee et incluant des complexes metalliques ; leur procede d'obtention et leurs applications en imagerie medicale et/ou therapie |
FR2989280B1 (fr) * | 2012-04-13 | 2017-02-24 | Univ Claude Bernard Lyon | Nanoparticules ultrafines comme agent de contraste multimodal |
JP6883046B2 (ja) * | 2015-11-06 | 2021-06-02 | ウイスコンシン アラムナイ リサーチ ファウンデーシヨンWisconsin Alumni Research Foundation | 長寿命ガドリニウムに基づく腫瘍標的化イメージングおよび治療薬 |
-
2017
- 2017-10-13 FR FR1759607A patent/FR3072281B1/fr active Active
-
2018
- 2018-10-12 TW TW107136007A patent/TWI791640B/zh active
- 2018-10-12 CN CN201880077921.4A patent/CN111565759B/zh active Active
- 2018-10-12 CA CA3078763A patent/CA3078763A1/fr active Pending
- 2018-10-12 EP EP18803733.7A patent/EP3694560A1/fr active Pending
- 2018-10-12 KR KR1020207013690A patent/KR20200071754A/ko not_active Application Discontinuation
- 2018-10-12 JP JP2020520446A patent/JP7321151B2/ja active Active
- 2018-10-12 US US16/755,866 patent/US11857604B2/en active Active
- 2018-10-12 AU AU2018347740A patent/AU2018347740B2/en active Active
- 2018-10-12 WO PCT/FR2018/052538 patent/WO2019073182A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
JP2020536907A (ja) | 2020-12-17 |
FR3072281B1 (fr) | 2020-12-04 |
AU2018347740B2 (en) | 2022-10-20 |
CN111565759B (zh) | 2024-03-26 |
TW201922225A (zh) | 2019-06-16 |
US20200289623A1 (en) | 2020-09-17 |
TWI791640B (zh) | 2023-02-11 |
US11857604B2 (en) | 2024-01-02 |
JP7321151B2 (ja) | 2023-08-04 |
AU2018347740A1 (en) | 2020-04-30 |
KR20200071754A (ko) | 2020-06-19 |
CA3078763A1 (fr) | 2019-04-18 |
FR3072281A1 (fr) | 2019-04-19 |
WO2019073182A1 (fr) | 2019-04-18 |
CN111565759A (zh) | 2020-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nik et al. | Smart drug delivery: Capping strategies for mesoporous silica nanoparticles | |
Zhou et al. | Chemically engineered mesoporous silica nanoparticles-based intelligent delivery systems for theranostic applications in multiple cancerous/non-cancerous diseases | |
Niculescu | Mesoporous silica nanoparticles for bio-applications | |
Secret et al. | Two-photon excitation of porphyrin-functionalized porous silicon nanoparticles for photodynamic therapy | |
Secret et al. | Anionic porphyrin-grafted porous silicon nanoparticles for photodynamic therapy | |
CN109663550B (zh) | 物质包封微囊及其制备方法 | |
JP4920056B2 (ja) | 癌標的性に優れたタンパク質複合体及びその製造方法 | |
EP3694560A1 (fr) | Nanovecteurs et utilisations | |
EP2563408A2 (fr) | Nanoparticules ultrafines a matrice polyorganosiloxane fonctionnalisee et incluant des complexes metalliques; leur procede d'obtention et leurs applications en imagerie medicale et/ou therapie | |
EP2831081B1 (fr) | Nanoparticules de silicium poreux fonctionnalisees et leurs utilisations en therapie photodynamique | |
FR2989280A1 (fr) | Nanoparticules ultrafines comme agent de contraste multimodal | |
Liu et al. | Redox/pH-responsive hollow manganese dioxide nanoparticles for thyroid cancer treatment | |
CA3011017A1 (fr) | Nanoparticules d'organosilice mesoporeuses, leur methode de preparation et leurs utilisations | |
EP4247435A1 (fr) | Procédé de préparation de nanoparticules | |
EP4013511A1 (fr) | Nanoparticules pour le traitement du cancer par rayonnement de radiofréquence | |
EP4247428A1 (fr) | Procédé de traitement de tumeurs par captation du cuivre et/ou du fer | |
Maleki et al. | Functionalized quantum dot–based nanomaterials for cancer therapy | |
Picchetti | Design and preparation of degradable organosilica particles for biomedical applications | |
Wang | Targeted and Controllable Dual Photothermo-Chemotherapy for Breast Cancer Based on Multifunctional Gold Nanoparticles | |
KR20230050952A (ko) | 광열 치료 및 광역학 치료가 가능한 암세포 표적 다공성 환원 그래핀 옥사이드 나노 복합체 및 이의 제조방법 | |
FR2981849A1 (fr) | Nanoparticules fonctionnalisees pour le ciblage des proteoglycanes et leurs applications | |
Della Rocca | Hybrid Nanoparticles for Anticancer Drug Delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200422 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: NH THERAGUIX |